Registered title, quoted from ClinicalTrials.gov
Clinical Study of Oncolytic Virus in Glioblastoma
An open trial on glioma, registered on ClinicalTrials.gov. Led by Mianyang Central Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07145047, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
Histologically confirmed recurrent glioblastoma.
Inclusion criterion 2
Before inclusion of patients in the study, at least one of the following types of therapy was previously performed: 4.1 Time from the last radiotherapy/surgery is more than 28 days; 4.2 Subjects maintained stable or declining for at least 7 days prior to corticosteroid regimen; 4.3 Most recent antitumor therapy must have been completed within the specified time prior to treatment: vincristine 2 weeks, nitrosoureas 4 weeks, bevacizumab 4 weeks, temozolomide 6 weeks.
Inclusion criterion 4
The subjects must agree to the use of an acceptable contraceptive method throughout the study, from the time informed consent is provided to 180 days after receiving treatment.
Inclusion criterion 7
Have poorly controlled clinical diseases, such as liver aminotransferase (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin > 2 times the upper normal limit.
Exclusion criterion 5
Magnetic resonance imaging (MRI) showed that the maximum diameter of recurrent lesions is greater than 1.0 cm.
Inclusion criterion 3
Female subjects: during pregnancy or lactation.
Exclusion criterion 6
Male or female patients who refused contraception during the study period and for 6 months after dosing.
Exclusion criterion 18
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07145047, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion criteria:
- Patients with recurrent glioblastoma, for whom the standard methods of treatment are considered ineffective by the medical commission.
- Histologically confirmed recurrent glioblastoma.
- Magnetic resonance imaging (MRI) showed that the maximum diameter of recurrent lesions is greater than 1.0 cm.
- Before inclusion of patients in the study, at least one of the following types of therapy was previously performed: 4.1 Time from the last radiotherapy/surgery is more than 28 days; 4.2 Subjects maintained stable or declining for at least 7 days prior to corticosteroid regimen; 4.3 Most recent antitumor therapy must have been completed within the specified time prior to treatment: vincristine 2 weeks, nitrosoureas 4 weeks, bevacizumab 4 weeks, temozolomide 6 weeks.
- Age >=18 years, <=70 years.
- Hematological indicators, kidney and liver function are normal.
- The subjects must agree to the use of an acceptable contraceptive method throughout the study, from the time informed consent is provided to 180 days after receiving treatment.
- Patient's ability to perform the study procedure and provide written informed consent in accordance with the GCP and local laws.
Exclusion criteria:
- Incompatibility of patients with the inclusion criteria mentioned above.
- Participated in other drug clinical trials within 4 weeks
- Preoperative bleeding susceptibility or use of anticoagulants or any medication that may increase the risk of bleeding.
- Patients with extracranial metastases.
- Have poorly controlled clinical diseases, such as liver aminotransferase (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)) or total bilirubin > 2 times the upper normal limit.
- Female subjects: during pregnancy or lactation.
- Uncontrolled active infection, unstable or severe concomitant disease of infection. Patients with immunodeficiency, autoimmune diseases, active HBV infection, HCV infection, or active HIV infection.
- Patients with a history of psychotropic substance abuse who are unable to quit or with mental disorders.
- Subjects had any active autoimmune disease or a history of autoimmune disease.
- Has a history of antiviral drug use within 1 week.
- Subjects are receiving immunosuppressive therapy, or concurrent chemotherapy, or radiation, or biotherapy.
- There are prohibited items for MRI, such as: pacemakers, epicardial pacemaker wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prostheses, potentially magnetic implants, metal objects in the eye, etc..
- History of substance abuse or known medical, or psychological, or social conditions, such as alcohol or drug abuse.
- Allergic, hypersensitive or intolerant to study oncolytic viruses (including any excipients).
- Vaccination within 30 days prior to administration.
- Patients who have received gene transfer therapy or treated with any type of oncolytic virus.
- History of encephalitis, or multiple sclerosis, or other central nervous system (CNS) infections, or primary CNS disease.
- Male or female patients who refused contraception during the study period and for 6 months after dosing.
- In the investigator's judgment, there is a serious concomitant disease that endangers the patient's safety or interferes with the patient's ability to complete the study.
Quoted from ClinicalTrials.gov, NCT07145047, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07145047, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.